• Animal Biome cat and dog digestion microbiome
    January 18, 2017
    Photo: AnimalBiome data scientist, Kari Goodman; CEO, Holly Ganz; and research scientist, Yvette Girard, at the JP Morgan CLSA event last week. It’s not uncommon for a pet dog or cat to have digestive issues, especially early in life. Instead of treating the root of the problem—an imbalance of good and bad bacteria in the gut—veterinarians commonly prescribe antibiotics. Without a true fix for the problem, pets can fall victim to a number of other health issues later in life as a result. Animal Biome is harnessing the power of the microbiome to make targeted therapeutics for dogs and cats that are suffering from digestive issues. We asked the company’s CEO, Holly Ganz, a few questions: – Tell me about your background, how did you get interested in the biotech space? Up until recently, I was an academic researcher working at UC Davis studying co-evolution between animals and microbes. I became interested in the biotech space ...
  • March 14, 2016
    Today, we stand on the brink of the fourth industrial revolution which fuses the physical, digital and biological spheres of technology that will fundamentally alter the way we all treat our health, eat sustainable and live better. This revolution which is being built by hundreds of startups around the world will have a biological base. IndieBio is pleased to announce the latest 15 IndieBio companies based here in San Francisco. Based in SF, they all have a global vision, hailing from all corners of the globe to change humanity through a blend of technology and biology. In alphabetic order: Amaryllis Nucleics Amaryllis empowers researchers by accelerating important discoveries in genomics. Our technology halves the time and reduces the cost of RNA sequencing by 8-fold to empower the cutting edge cancer diagnostics, pharmaceutical development, and food security innovations. Ardra Natural and petroleum free products are the fastest growing category in cosmetics, worth over $23B globally. Ardra is engineering technologies to produce ...
  • julie_
    February 2, 2016
    Even though biotech has a huge impact on the lives of the general public, it is an intimidating and foreign space to many. The everyday person rarely feels like they can understand and play a role in this massive field. Amino Labs is making science accessible to the masses by creating an easy to use biokit for the consumer home. I spoke with Julie, the CEO, about her unexpected path to biotech, approaching the field from design, and the impact of an at-home biokit. Check out her pitch live on February 4th on IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get interested in the biotech space? J: I never imagined I would become involved in the biotech space, to be quite honest. It seemed very foreign, complex and closed-off considering my background is in Design and Applied Arts. I’ve been focused on translating important technological advancement into understandable ...
  • Anitha Girihlet
    January 28, 2016
    The immune system is the cornerstone of our health and ability to fight disease, but there are no methods to truly monitor its status. As a result, medicine is forced into being reactive to illness, rather than fighting disease before it starts. Girihlet is working towards a future where the immune system is monitored at every doctor’s visit and we can predict our resilience to disease before it happens. I talked with Anitha, one of the co-founders, about how her team is tackling this problem, the future of Girihlet, and how this technology can change public health. Check out her pitch live on February 4th on IndieBio’s Demo Day Livestream!   AK: Tell me about your background, how did you get interested in the biotech space? AJ: I’ve always been interested in the field of biology and all the processes going on inside the human body so it was natural for me to go to ...
  • Henrik
    January 28, 2016
    Modern neuroscience is still relying on old methods that don’t allow us to truly understand what’s happening in the brain in real-time. As a result, we have a limited understanding of brain-related disease and ability to treat conditions early. Truust’s neuroimaging technology is providing real-time data in order to visualize energy flow in the brain, and, as a result, be able to predict and treat brain-related diseases before they start. I spoke with the Henrik, the CEO, to learn how he discovered this problem, limitations of today’s technology, and how Truust can change the field. Check out his pitch from IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get interested in the biotech space? H: I met my co-founder, Lars, about 15 years ago, while working as an electrical engineer. As a result of the computational problems presented while working on the Semantic Web I got interested in artificial ...
  • Andrew Gray, Vali
    January 27, 2016
    Drug delivery is one of the greatest challenges in treating cancer today. There are a multitude of effective drugs that aren’t able to be delivered to tumor sites, or can not be delivered in combination. Vali Nanomedical is now solving these drug delivery problems with a revolutionary programmable drug delivery system, and working towards a future where in vivo cellular reprogramming can cure disease without even using drugs. I talked with Andrew, Vali’s CEO, about his path to entrepreneurship, its challenges, and the future of Vali. Check out his pitch from IndieBio’s Demo Day Livestream!   AK: Tell me about your background, how did you get interested in the biotech space? AG: I have PhD in molecular biology, focusing on cancer and developing cancer vaccines as a grad student. I got involved in nanotech knowing that starting a company was the goal. Early on I took a class on entrepreneurship and knew right away that ...
  • jun
    January 27, 2016
    Next-generation DNA sequencing technology has revolutionized biological research over the last decade, but very few advancements have been made in proteomics, the next great frontier of biological data. MYi is developing these new methods to study proteins in order to better understand, manage, and cure disease. I spoke with Jun, the company’s COO, to learn about the team’s expertise, the potential of the field of proteomics, and the impact MYi hopes to have. Check out her pitch live on February 4th on IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get interested in the biotech space? J: Our team knew each other from our time at The Scripps Research Institute, where I obtained my Ph.D. in chemical biology. I’ve always wanted to apply my work to therapeutics, but after working in that industry, I realized the slow pace of biological discovery. Leaps in innovation only happen after technological breakthroughs ...
  • 737805_10101479424867561_755626567_o (2)
    January 26, 2016
    Tracking vital signs is a crucial means for preventing disease. However, it’s a big time demand on caretakers of the most vulnerable patients and rarely done for much of the general population. V-Sense is developing monitors using NASA Jet Propulsion Lab radar technology to remotely and continuously monitor key vital signs. I talked to the company’s CEO, Jeff Nosanov, about learning how to apply this new technology, lessons moving from research to startups, and goals for V-Sense. Check out his pitch live on February 4th on IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get interested in the biotech space? J: I always wanted to be an astronaut and started college in engineering because of this. I later switched out to approach the space world from a different angle and got the first ever Space and Telecommunication Law degree. That got me my job at NASA Jet Propulsion ...
  • Dominique Barnes, NWF
    January 26, 2016
    As the population keeps growing, we are increasingly turning to our oceans to feed a hungry world. This pressure is leading to unsustainable practices that damage ecosystems and our health. New Wave Foods is creating healthy and sustainable plant and algae-based seafood to meet this growing demand. I talked to the company’s CEO, Dominique Barnes, to learn more about this issue, her team’s expertise, and how New Wave Foods can change how we eat. Check out her pitch live on February 4th on IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get interested in the biotech space? My background is in Marine Conservation and hospitality. I saw biotech as a way to solve overfishing pressures on our oceans.   A: What problem are you working to solve with your company, New Wave Foods? We’re working to solve the global issue of feeding over 10 billion people by 2050. The current seafood supply ...
  • Paul Feldstein headshot cropped
    January 25, 2016
    Cellular protein production is used across industries to create products for medicine, consumers, research, and more. However, the technology to do so in the most efficient and effective ways has lagged behind production. Circularis is using their expertise in discovering, analyzing, and evolving cellular promoters in order to regulate protein production with revolutionary precision. I talked to the company’s CEO, Paul Feldstein, about his team’s expertise, taking this advanced technology from academia to startups, and how Circularis will push biotech forward. Check out his pitch live on February 4th on IndieBio’s Demo Day Livestream!   A: Tell me about your background, how did you get involved in the biotech space? P: I received my PhD at UC Davis in biochemistry and worked in one of the pioneering ribozyme (catalytic RNA) labs. So my background is in RNA biochemistry, and I have been working on research with the most primitive molecular parasites. These are made of ...